Robot-assisted kidney transplantation (RAKT) may reduce surgical complications compared to open kidney transplantation (OKT), but no randomised trials have explored this to date. The aim of the present study is to explore the feasibility of introducing RAKT at our institution, making it available in deceased donor transplantation and evaluate early surgical outcomes prior to performing a randomised trial comparing RAKT to OKT. RAKT was performed at Department of Urology, Copenhagen University Hospital, Rigshospitalet, Denmark. The patients were included from June 2022 until May 2023. The data were collected through the national electronic health records. The data include recipient, donor and intraoperative characteristics, postoperative complications within 90 days graded according to Clavien-Dindo classification and days alive and out of hospital (DAOH). The functional outcomes include eGFR, plasma creatinine, delayed graft function, and rejection episodes. Sixteen RAKTs were performed. Fourteen cases were transplantations with living donors and two cases were with deceased donors. There were no major intra-operative adverse events and no conversions. The median operative time was 223 min and median blood loss 150 ml. The median length of stay was 7 days and median DAOH was 82. Seven complications occurred in five patients at 90 days postoperatively; however, there were no major surgical complications. This study comprehensively assesses patient morbidity following RAKT in a small cohort with results indicating favourable outcomes. This supported our clinical assumption of reduced complications for a randomised trial comparing OKT and RAKT (the ORAKTx trial) which has been initiated (NCT identifier 05730257).
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703890 | PMC |
http://dx.doi.org/10.1007/s11701-024-02190-4 | DOI Listing |
Kidney360
January 2025
Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, CA.
Background: 'Life Years from Transplant' (LYFT) is a measure of the predicted difference between the expected lifespan with and without a kidney transplant. The metric was originally proposed in 1999; since then, demographics of the kidney transplant candidate population have materially changed.
Methods: Using contemporary SRTR data, we propose more sophisticated methods for estimating LYFT with a focus on older kidney transplant candidates, a growing sector of the current candidate pool.
Sci Transl Med
January 2025
Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA.
Long-term, immunosuppression-free allograft survival has been induced in human and nonhuman primate (NHP) kidney recipients after nonmyeloablative conditioning and donor bone marrow transplantation (DBMT), resulting in transient mixed hematopoietic chimerism. However, the same strategy has consistently failed in NHP heart transplant recipients. Here, we investigated whether long-term heart allograft survival could be achieved by cotransplanting kidneys from the same donor.
View Article and Find Full Text PDFPediatr Nephrol
January 2025
Department of Pediatrics, University of California, San Diego, 3020 Children's Way MC 5173, San Diego, CA, 92123, USA.
Proliferative Glomerulonephritis with Monoclonal IgG Deposits (PGNMID) is a glomerular disease characterized by membranoproliferative and mesangioproliferative lesions, with granular capillary wall monoclonal IgG positivity and immunoglobulin light chain restriction. Most commonly a disease of older adults, we present the case of an 18-year-old patient who developed de novo PGNMID in a kidney allograft three years after kidney transplantation. There was minimal proteinuria and no serum paraproteinemia was detected, so the patient was managed conservatively.
View Article and Find Full Text PDFPediatr Nephrol
January 2025
Center for HUS Prevention, Control and Management at the Pediatric Nephrology, Dialysis and Transplantation Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Background: C3 glomerulopathy (C3G) is a rare kidney disease due to a dysregulation of the alternative complement pathway, orphan of specific treatment. Pegcetacoplan is an inhibitor of the third complement component C3, currently on a phase III registration protocol in C3G. Here we describe our experience with the off-label use of pegcetacoplan in pediatric patients with C3G.
View Article and Find Full Text PDFEur J Anaesthesiol
January 2025
From the Department of Anaesthesia, King's College Hospital NHS Foundation Trust, London, UK (BM, GK), Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, UK (KM, MM), Department of Critical Care, Guy's & St Thomas' NHS Foundation Trust, London, UK (MO), Department of Critical Care, University of Pittsburgh, USA (JAK), School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, UK (GK).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!